Maximum quantity allowed is 999
CAS RN: 36322-90-4 | Product Number: P1905
Piroxicam
Purity: >98.0%(T)(HPLC)
- 4-Hydroxy-2-methyl-3-(2-pyridylcarbamoyl)-2H-1,2-benzothiazine 1,1-Dioxide
- 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-Dioxide
* Please contact our distributors or
TCI
to order our products. The above prices do not include freight cost, customs, and other charges to the destination.
* The storage conditions are subject to change without notice.
| Product Number | P1905 |
Purity / Analysis Method
|
>98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__1__5H__1__3N__3O__4S = 331.35 |
| Physical State (20 deg.C) | Solid |
Storage Temperature
|
Refrigerated (0-10°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Air Sensitive,Heat Sensitive |
| CAS RN | 36322-90-4 |
| Reaxys Registry Number | 627692 |
| PubChem Substance ID | 125307705 |
| Merck Index (14) | 7506 |
| MDL Number | MFCD00057317 |
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| Melting point | 199.0 to 203.0 °C |
| NMR | confirm to structure |
| Melting Point | 201 °C |
| Maximum Absorption Wavelength | 358 nm (H__2O) |
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H301 : Toxic if swallowed. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth. P405 : Store locked up. |
| RTECS# | DL0705000 |
| UN Number | UN2811 |
| Class | 6.1 |
| Packing Group | III |
| H.S.code* | 2934.99-000 |
References
- Piroxicam. A reappraisal of its pharmacology and therapeutic efficacy (a review)
- Human synovial mast cell. II. Heterogeneity of the pharmacologic effects of antiinflammatory and immunosuppressive drugs
- Chemoprevention of spontaneous intestinal adenomas in the ApcMin mouse model by the nonsteroidal anti-inflammatory drug piroxicam
- Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulators and specificity of modifiers
- Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer
- Piroxicam (a review on physical properties, synthesis, stability, methods of analysis and pharmacokinetics of piroxicam)
Documents
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
The requested SDS is not available.
Specifications
The requested specifications are not available.
Please Contact Us for more information.
The requested specifications are not available.
C of A & Other Certificates
Please check that the lot number you have entered is correct. It is 4-5 alphanumeric characters before the hyphen. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
If your information is correct and you are still not able to view the requested certificates, Please Contact Us for more information.
Please check that the lot number you have entered is correct. It is 7 alphanumeric characters. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
Sample C of A
A sample C of A for this product is not available at this time.
Analytical Charts
The requested analytical chart is not available. Sorry for the inconvenience.